Habitat radiomics analysis for progression free survival and immune-related adverse reaction prediction in non-small cell lung cancer treated by immunotherapy
Abstract Background Non-small cell lung cancer (NSCLC) is highly heterogeneous, leading to varied treatment responses and immune-related adverse reactions (irAEs) among patients. Habitat radiomics allows non-invasive quantitative assessment of intratumor heterogeneity (ITH). Therefore, our objective...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-024-06057-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850265383235223552 |
|---|---|
| author | Yuemin Wu Wei Zhang Xiao Liang Pengpeng Zhang Mengzhe Zhang Yuqin Jiang Yanan Cui Yi Chen Wenxin Zhou Qi Liang Jiali Dai Chen Zhang Jiali Xu Jun Li Tongfu Yu Zhihong Zhang Renhua Guo |
| author_facet | Yuemin Wu Wei Zhang Xiao Liang Pengpeng Zhang Mengzhe Zhang Yuqin Jiang Yanan Cui Yi Chen Wenxin Zhou Qi Liang Jiali Dai Chen Zhang Jiali Xu Jun Li Tongfu Yu Zhihong Zhang Renhua Guo |
| author_sort | Yuemin Wu |
| collection | DOAJ |
| description | Abstract Background Non-small cell lung cancer (NSCLC) is highly heterogeneous, leading to varied treatment responses and immune-related adverse reactions (irAEs) among patients. Habitat radiomics allows non-invasive quantitative assessment of intratumor heterogeneity (ITH). Therefore, our objective is to employ habitat radiomics techniques to develop a robust approach for predicting the efficacy of Immune checkpoint inhibitors (ICIs) and the likelihood of irAEs in advanced NSCLC patients. Methods In this retrospective two center study, two independent cohorts of patients with NSCLC were used to develop (n = 248) and validate signatures (n = 95). After applying four kinds of machine learning algorithms to select the key preoperative CT radiomic features, we used clinical, radiomics and habitat radiomic features to develop the clinical signature, radiomics signature and habitat radiomic signature for ICIs prognostics and irAEs prediction. By combining habitat radiomic features with corresponding clinicopathologic information, the nomogram signature was constructed in the training cohort. Next, the internal validation cohort (n = 75) of patients, and the external validation cohort (n = 20) of patients treated with ICIs were included to evaluate the predictive value of the four signatures, and their predictive performance was assessed by the area under operating characteristic curve (AUC). Results Our study introduces a radiomic nomogram model that integrates clinical and habitat radiomic features to identify patients who may benefit from ICIs or experience irAEs. The Radiomics Nomogram model exhibited superior predictive performance in the training, validation, and external validation sets, with AUCs of 0.923, 0.817, and 0.899, respectively. This model outperformed both the Whole-tumor Radiomics Signature model (AUCs of 0.870, 0.736, and 0.626) and the Habitat Signature model (AUCs of 0.900, 0.804, and 0.808). The radiomics model focusing on tumor sub-regional habitat showed better predictive performance than the model derived from the entire tumor. Decision Curve Analysis (DCA) and calibration curves confirmed the nomogram’s effectiveness. Conclusion By leveraging machine learning to predict the outcomes of ICIs, we can move closer to achieving tailored ICIs for lung cancer. This advancement will assist physicians in selecting and managing subsequent treatment strategies, thereby facilitating clinical decision-making. |
| format | Article |
| id | doaj-art-ff6f3b8ba23a49188d2e77ff9d0ae12b |
| institution | OA Journals |
| issn | 1479-5876 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj-art-ff6f3b8ba23a49188d2e77ff9d0ae12b2025-08-20T01:54:26ZengBMCJournal of Translational Medicine1479-58762025-04-0123111910.1186/s12967-024-06057-yHabitat radiomics analysis for progression free survival and immune-related adverse reaction prediction in non-small cell lung cancer treated by immunotherapyYuemin Wu0Wei Zhang1Xiao Liang2Pengpeng Zhang3Mengzhe Zhang4Yuqin Jiang5Yanan Cui6Yi Chen7Wenxin Zhou8Qi Liang9Jiali Dai10Chen Zhang11Jiali Xu12Jun Li13Tongfu Yu14Zhihong Zhang15Renhua Guo16Department of Oncology, First Affiliated Hospital, Nanjing Medical UniversityDepartment of Radiology, First Affiliated Hospital, Nanjing Medical UniversityDepartment of Oncology, First Affiliated Hospital, Nanjing Medical UniversityDepartment of Lung Cancer Surgery, Tianjin Lung Cancer Institute, Tianjin Medical University Cancer Institute and HospitalDepartment of Lung Cancer Surgery, Tianjin Lung Cancer Institute, Tianjin Medical University Cancer Institute and HospitalDepartment of Oncology, First Affiliated Hospital, Nanjing Medical UniversityDepartment of Radiology, First Affiliated Hospital, Nanjing Medical UniversityDepartment of Oncology, Pukou Branch of Jiangsu People’s Hospital, Nanjing Pukou District Central HospitalDepartment of Oncology, First Affiliated Hospital, Nanjing Medical UniversityDepartment of Oncology, First Affiliated Hospital, Nanjing Medical UniversityDepartment of Oncology, First Affiliated Hospital, Nanjing Medical UniversityDepartment of Oncology, First Affiliated Hospital, Nanjing Medical UniversityDepartment of Oncology, First Affiliated Hospital, Nanjing Medical UniversityDepartment of Oncology, First Affiliated Hospital, Nanjing Medical UniversityDepartment of Radiology, First Affiliated Hospital, Nanjing Medical UniversityDepartment of Pathology, First Affiliated Hospital, Nanjing Medical UniversityDepartment of Radiology, First Affiliated Hospital, Nanjing Medical UniversityAbstract Background Non-small cell lung cancer (NSCLC) is highly heterogeneous, leading to varied treatment responses and immune-related adverse reactions (irAEs) among patients. Habitat radiomics allows non-invasive quantitative assessment of intratumor heterogeneity (ITH). Therefore, our objective is to employ habitat radiomics techniques to develop a robust approach for predicting the efficacy of Immune checkpoint inhibitors (ICIs) and the likelihood of irAEs in advanced NSCLC patients. Methods In this retrospective two center study, two independent cohorts of patients with NSCLC were used to develop (n = 248) and validate signatures (n = 95). After applying four kinds of machine learning algorithms to select the key preoperative CT radiomic features, we used clinical, radiomics and habitat radiomic features to develop the clinical signature, radiomics signature and habitat radiomic signature for ICIs prognostics and irAEs prediction. By combining habitat radiomic features with corresponding clinicopathologic information, the nomogram signature was constructed in the training cohort. Next, the internal validation cohort (n = 75) of patients, and the external validation cohort (n = 20) of patients treated with ICIs were included to evaluate the predictive value of the four signatures, and their predictive performance was assessed by the area under operating characteristic curve (AUC). Results Our study introduces a radiomic nomogram model that integrates clinical and habitat radiomic features to identify patients who may benefit from ICIs or experience irAEs. The Radiomics Nomogram model exhibited superior predictive performance in the training, validation, and external validation sets, with AUCs of 0.923, 0.817, and 0.899, respectively. This model outperformed both the Whole-tumor Radiomics Signature model (AUCs of 0.870, 0.736, and 0.626) and the Habitat Signature model (AUCs of 0.900, 0.804, and 0.808). The radiomics model focusing on tumor sub-regional habitat showed better predictive performance than the model derived from the entire tumor. Decision Curve Analysis (DCA) and calibration curves confirmed the nomogram’s effectiveness. Conclusion By leveraging machine learning to predict the outcomes of ICIs, we can move closer to achieving tailored ICIs for lung cancer. This advancement will assist physicians in selecting and managing subsequent treatment strategies, thereby facilitating clinical decision-making.https://doi.org/10.1186/s12967-024-06057-yNon-small cell lung cancerMachine learningHabitat radiomicsTumor microenvironmentImmune-related adverse events |
| spellingShingle | Yuemin Wu Wei Zhang Xiao Liang Pengpeng Zhang Mengzhe Zhang Yuqin Jiang Yanan Cui Yi Chen Wenxin Zhou Qi Liang Jiali Dai Chen Zhang Jiali Xu Jun Li Tongfu Yu Zhihong Zhang Renhua Guo Habitat radiomics analysis for progression free survival and immune-related adverse reaction prediction in non-small cell lung cancer treated by immunotherapy Journal of Translational Medicine Non-small cell lung cancer Machine learning Habitat radiomics Tumor microenvironment Immune-related adverse events |
| title | Habitat radiomics analysis for progression free survival and immune-related adverse reaction prediction in non-small cell lung cancer treated by immunotherapy |
| title_full | Habitat radiomics analysis for progression free survival and immune-related adverse reaction prediction in non-small cell lung cancer treated by immunotherapy |
| title_fullStr | Habitat radiomics analysis for progression free survival and immune-related adverse reaction prediction in non-small cell lung cancer treated by immunotherapy |
| title_full_unstemmed | Habitat radiomics analysis for progression free survival and immune-related adverse reaction prediction in non-small cell lung cancer treated by immunotherapy |
| title_short | Habitat radiomics analysis for progression free survival and immune-related adverse reaction prediction in non-small cell lung cancer treated by immunotherapy |
| title_sort | habitat radiomics analysis for progression free survival and immune related adverse reaction prediction in non small cell lung cancer treated by immunotherapy |
| topic | Non-small cell lung cancer Machine learning Habitat radiomics Tumor microenvironment Immune-related adverse events |
| url | https://doi.org/10.1186/s12967-024-06057-y |
| work_keys_str_mv | AT yueminwu habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT weizhang habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT xiaoliang habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT pengpengzhang habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT mengzhezhang habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT yuqinjiang habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT yanancui habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT yichen habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT wenxinzhou habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT qiliang habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT jialidai habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT chenzhang habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT jialixu habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT junli habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT tongfuyu habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT zhihongzhang habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy AT renhuaguo habitatradiomicsanalysisforprogressionfreesurvivalandimmunerelatedadversereactionpredictioninnonsmallcelllungcancertreatedbyimmunotherapy |